Two Sigma Advisers LP Acquires 55,000 Shares of Arvinas, Inc. (NASDAQ:ARVN)

Two Sigma Advisers LP raised its position in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 24.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 282,600 shares of the company's stock after purchasing an additional 55,000 shares during the period. Two Sigma Advisers LP owned 0.41% of Arvinas worth $5,417,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Invesco Ltd. grew its holdings in Arvinas by 1.6% during the fourth quarter. Invesco Ltd. now owns 37,254 shares of the company's stock valued at $714,000 after purchasing an additional 581 shares during the period. Rhumbline Advisers grew its holdings in Arvinas by 0.9% during the fourth quarter. Rhumbline Advisers now owns 87,877 shares of the company's stock valued at $1,685,000 after purchasing an additional 754 shares during the period. Bank of Montreal Can grew its holdings in Arvinas by 2.7% during the fourth quarter. Bank of Montreal Can now owns 39,407 shares of the company's stock valued at $755,000 after purchasing an additional 1,044 shares during the period. KBC Group NV grew its holdings in Arvinas by 77.0% during the fourth quarter. KBC Group NV now owns 2,885 shares of the company's stock valued at $55,000 after purchasing an additional 1,255 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Arvinas by 3.8% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,514 shares of the company's stock valued at $700,000 after purchasing an additional 1,353 shares during the period. 95.19% of the stock is owned by institutional investors.

Insider Activity at Arvinas

In other news, insider Noah Berkowitz sold 8,658 shares of the firm's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total transaction of $74,372.22. Following the transaction, the insider now directly owns 110,023 shares of the company's stock, valued at approximately $945,097.57. This trade represents a 7.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.73% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Wedbush downgraded Arvinas from an "outperform" rating to a "neutral" rating and dropped their target price for the stock from $57.00 to $12.00 in a research report on Wednesday, March 12th. HC Wainwright dropped their target price on Arvinas from $81.00 to $24.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Guggenheim dropped their target price on Arvinas from $32.00 to $16.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. UBS Group dropped their target price on Arvinas from $74.00 to $21.00 and set a "buy" rating on the stock in a research report on Thursday, May 15th. Finally, Stifel Nicolaus dropped their target price on Arvinas from $63.00 to $51.00 and set a "buy" rating on the stock in a research report on Wednesday, February 12th. Eight research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $20.92.

Arvinas Stock Performance

ARVN traded down $0.42 during trading on Friday, reaching $7.09. The stock had a trading volume of 530,090 shares, compared to its average volume of 1,358,559. The stock has a market cap of $517.14 million, a PE ratio of -2.55 and a beta of 2.21. Arvinas, Inc. has a one year low of $5.90 and a one year high of $34.34. The business has a 50-day moving average of $7.34 and a 200-day moving average of $14.84.

Arvinas (NASDAQ:ARVN - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $1.14 EPS for the quarter, beating analysts' consensus estimates of ($0.93) by $2.07. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. The company's revenue was up 646.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.97) EPS. Equities research analysts forecast that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.